Starting Dose of Insulin Glargine for Type 2 DM with HbA1c 12% and CBG 300 mg/dL
For this patient with severe hyperglycemia (HbA1c 12%, blood glucose 300 mg/dL), start insulin glargine at 0.2 units/kg once daily, which is the appropriate FDA-approved starting dose for insulin-naive type 2 diabetes patients with markedly elevated glucose levels 1.
Rationale for This Approach
Given the severity of hyperglycemia in this case, insulin is clearly indicated as first-line therapy. The 2025 ADA guidelines specifically recommend considering insulin when A1C >10% or blood glucose ≥300 mg/dL 2. Your patient meets both criteria, making insulin glargine an appropriate choice.
Specific Dosing Strategy
The FDA label provides two starting dose options for insulin-naive type 2 diabetes patients 1:
- 0.2 units/kg once daily (preferred for severe hyperglycemia)
- Up to 10 units once daily (more conservative option)
For this patient with HbA1c 12% and glucose 300 mg/dL, use the weight-based dosing of 0.2 units/kg rather than the flat 10-unit dose. This higher starting dose is justified by the marked hyperglycemia and will achieve glycemic targets more rapidly while remaining safe 3, 4.
Calculation Example
- If patient weighs 80 kg: 80 × 0.2 = 16 units once daily
- If patient weighs 100 kg: 100 × 0.2 = 20 units once daily
Titration Protocol
After initiation, titrate aggressively but safely:
- Increase by 2-4 units once or twice weekly until fasting plasma glucose reaches 80-130 mg/dL 3
- Monitor fasting blood glucose daily during titration
- Target fasting glucose of 80-130 mg/dL initially 2
- Expect to reach maintenance doses of 40-70 units/day in many patients 5
A practical titration algorithm 5:
- FPG <4.4 mmol/L (79 mg/dL): decrease by 2 units
- FPG 4.4-7.0 mmol/L (79-126 mg/dL): no change
- FPG 7.1-10.0 mmol/L (127-180 mg/dL): increase by 2 units
- FPG >10.0 mmol/L (>180 mg/dL): increase by 4 units
Administration Timing
Administer once daily at the same time each day - either morning or evening based on patient preference 1. Recent evidence shows no significant difference in efficacy or hypoglycemia risk between morning and evening dosing 6, so choose the time that best fits the patient's lifestyle to optimize adherence.
Critical Considerations
Do not use the conservative 10-unit starting dose for this patient. While 10 units is appropriate for patients with mild hyperglycemia, this patient's severe hyperglycemia (HbA1c 12%, glucose 300) requires more aggressive initial dosing to prevent prolonged exposure to glucotoxicity 4.
Consider adding or continuing GLP-1 receptor agonists if not contraindicated. The 2025 ADA guidelines emphasize combination therapy with GLP-1 RAs when starting insulin, as this can improve outcomes and reduce insulin requirements 2.
Monitor for hypoglycemia during titration, though risk is relatively low with basal insulin alone. Educate the patient on recognition and treatment of hypoglycemia before starting insulin 1.
Expected Outcomes
With appropriate dosing and titration:
- Expect HbA1c reduction of 1.5-2.5% 5
- Approximately 50% of patients achieve HbA1c ≤7% with basal insulin alone 5
- Average weight gain around 3 kg over 6 months 5
- Fasting glucose should decrease by approximately 3.2 mmol/L (59 mg/dL) 7
Avoid overbasalization - if basal insulin doses exceed 0.5-1.0 units/kg/day without achieving targets, consider adding prandial insulin or intensifying other glucose-lowering therapies rather than continuing to escalate basal insulin 2, 3.